Detailed review on phytosomal formulation attenuating new pharmacological therapies

Nowadays, numerous diseases are benefitted from phytosomal therapy. However, poor selectivity and bioavailability may be limiting factors of their therapeutic applicability. The distribution of hydrophobic phytochemicals has been proposed as a potential use for nanovesicles. Phytosomes are more stable, according to a recent assessment of the literature, since a chemical link is created between the phospholipid molecules and the phytoconstituent. Fewer phytoconstituents are needed, extending the action, and they are more bioavailable in their complex form. Due to the easy preparation of the bilayer vesicles and their adaptability, they have been widely used and approved by the scientific literature. In this review paper we describe the promising clinical and experimental findings of more than 100 phytosomal studies. The effects of phytosomes on the immunological, circulatory, gastrointestinal, genitourinary, respiratory, integumentary, central and peripheral nervous systems, and musculoskeletal systems have all been studied according to the research compiled. These results confirm the greater effectiveness of phytosomes, both in terms of biological activity or reduced dosage, highlighting curcumin and silymarin as the most formulated compounds. Using such formulations to increase the bioactivity of phytochemicals and their bioavailability generally has advantages, allowing for lower dosages or higher biological activity as compared to using unformulated compounds. The conclusion of this study encourages the researchers to transfer their findings from research laboratories to market, for a further development of these products. The potential role of phytophospholipid complexes has a promising future for pharmaceutical applications with the help of physicians and other researchers.